Abstract
Expression of the B-Myb transcription factor is directed by an E2F-dependent transcriptional mechanism to late G1 and S phases of the cell cycle, where its transactivation properties are enhanced post-translationally by cyclin A/Cdk2-mediated phosphorylation. Other experiments have shown that removal of the B-Myb C-terminus constitutively activates both transactivation and DNA-binding activities, suggesting that autoregulation by this inhibitory domain is counteracted by phosphorylation. We report here on further experiments to examine this hypothesis. The importance of this modification was first emphasized by showing that co-transfected dominant-negative Cdk2 (Cdk2DN) substantially reduced B-Myb transactivation activity. We then attempted to map the autoregulatory domain by analysing a series of progressively deleted C-terminal B-Myb mutants. Removal of just 29 C-terminal aa increased transactivation appreciably, however, maximal activity required removal of 143 amino acids (as in B-Myb+561). Enhanced B-Myb+561 function correlated with the acquisition of DNA binding activity to a single Myb binding site (MBS) oligonucleotide as determined by bandshift assays, however, further assays showed that even wt B-Myb could bind a DNA fragment containing three MBS. Although transactivation by B-Myb was severely dependent on hyperphosphorylation, neither inhibiting this activity by co-transfecting Cdk2DN nor augmenting it with cyclin A resulted in significant effects on DNA-binding. We also found that B-Myb could synergize with the CBP coactivator and that this cooperativity was cyclin A/Cdk2-dependent. Despite this, the physical association between these proteins was not influenced by the B-Myb phosphorylation status. We discuss these findings in relation to the autoregulation of B-Myb by the C-terminal domain.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ansieau S, Kowentz-Leutz E, Dechend R, Leutz A . 1997 J. Mol. Med. 75: 815–819
Arsura M, Introna M, Passerini F, Mantovani A, Golay J . 1992 Blood 79: 2708–2716
Bartsch O, Horstmann S, Toprak K, Klempnauer KH, Ferrari S . 1999 Eur. J. Biochem. 260: 384–391
Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH . 1988 Nature 335: 835–837
Bies J, Hoffman B, Amanullah A, Giese T, Wolff L . 1996 Oncogene 12: 355–363
Cervellera MN, Sala A . 2000 J. Biol. Chem. 275: 10692–10696
Charrasse S, Carena I, Brondani V, Klempnauer KH, Ferrari S . 2000 Oncogene 19: 2986–2995
Chrivia J, Kwok RPS, Lamb N, Hagiwara M, Montminy MR, Goodman RH . 1993 Nature 365: 855–859
Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S . 1996 Genes Dev. 10: 528–540
Dash AB, Orrico FC, Ness SA . 1996 Genes Dev. 10: 1858–1869
De Falco G, Bagella L, Claudio PP, De Luca A, Fu Y, Calabretta B, Sala A, Giordano A . 2000 Oncogene 19: 373–379
Dubendorff JW, Whittaker LJ, Eltman JT, Lipsick JS . 1992 Genes Dev. 6: 2524–2535
Facchinetti V, Loffarelli L, Schreek S, Oelgeschlager M, Luscher B, Introna M, Golay J . 1997 Biochem. J. 324: 729–736
Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M . 1991 Blood 77: 149–158
Horstmann S, Ferrari S, Klempnauer KH . 2000 Oncogene 19: 298–306
Howe KM, Reakes CF, Watson RJ . 1990 EMBO J. 9: 161–169
Hu YL, Ramsay RG, Kanei IC, Ishii S, Gonda TJ . 1991 Oncogene 6: 1549–1553
Humbert-Lan G, Pieler T . 1999 J. Biol. Chem. 274: 10293–10300
Johnson TK, Schweppe RE, Septer J, Lewis RE . 1999 J. Biol. Chem. 274: 36741–36749
Kalkbrenner F, Guehmann S, Moelling K . 1990 Oncogene 5: 657–661
Kamano H, Burk B, Noben-Trauth K, Klempnauer KH . 1995 Oncogene 11: 2575–2582
Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S, Ishii S, Gonda TJ . 1992 Proc. Natl. Acad. Sci. USA 89: 3088–3092
Lam EW, Robinson C, Watson RJ . 1992 Oncogene 7: 1885–1890
Lam EW-F, Bennett J, Watson RJ . 1995 Gene 160: 277–281
Lam EW-F, Morris JDH, Davies R, Crook T, Watson RJ, Vousden KH . 1994 EMBO J. 13: 871–878
Lam EW-F, Watson RJ . 1993 EMBO J. 12: 2705–2713
Lane S, Farlie P, Watson R . 1997 Oncogene 14: 2445–2453
Miglarese MR, Richardson AF, Aziz N, Bender TP . 1996 J. Biol. Chem. 271: 22697–22705
Morris L, Allen KE, La Thangue NB . 2000 Nat. Cell Biol. 2: 232–239
Ness SA, Marknell A, Graf T . 1989 Cell 59: 1115–1125
Nakagoshi H, Takemoto Y, Ishii S . 1993 J. Biol. Chem. 268: 14161–14167
Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, Ishizaki R . 1988 Nucleic Acids Res. 16: 11075–11089
Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B . 1996 EMBO J. 15: 2771–2780
Ramsay RG, Ishii S, Gonda TJ . 1991 Oncogene 6: 1875–1879
Raschella G, Negroni A, Sala A, Pucci S, Romeo A, Calabretta B . 1995 J. Biol. Chem. 270: 8540–8545
Reiss K, Travali S, Calabretta B, Baserga R . 1991 J. Cell. Physiol. 148: 338–343
Robinson C, Light Y, Groves R, Mann D, Marais R, Watson R . 1996 Oncogene 12: 1855–1864
Sala A, Calabretta B . 1992 Proc. Natl. Acad. Sci. USA 89: 10415–10419
Sala A, De-Luca A, Giordano A, Peschle C . 1996 J. Biol. Chem. 271: 28738–28740
Sala A, Kundu M, Casella I, Engelhard A, Calabretta B, Grasso L, Paggi MG, Giordano A, Watson RJ, Khalili K, Peschle C . 1997 Proc. Natl. Acad. Sci. USA 94: 532–536
Sala A, Saitta B, De Luca P, Cervellera MN, Casella I, Lewis RE, Watson R, Peschle C . 1999 Oncogene 18: 1333–1339
Sano Y, Ishii S . 2001 J. Biol. Chem. 276: 3674–3682
Saville MK, Watson RJ . 1998 Oncogene 17: 2679–2689
Sitzmann J, Noben-Trauth K, Kamano H, Klempnauer KH . 1996 Oncogene 12: 1889–1894
Takahashi T, Nakagoshi H, Sarai A, Nomura N, Yamamoto T, Ishii S . 1995 FEBS Lett. 358: 89–96
Tanaka Y, Patestos NP, Maekawa T, Ishii S . 1999 J. Biol. Chem. 274: 28067–28070
Tashiro S, Takemoto Y, Handa H, Ishii S . 1995 Oncogene 10: 1699–1707
Tomita A, Towatari M, Tsuzuki S, Hayakawa F, Kosugi H, Tamai K, Miyazaki T, Kinoshita T, Saito H . 2000 Oncogene 19: 444–451
Vorbrueggen G, Lovric J, Moelling K . 1996 Biol. Chem. 377: 721–730
Watson RJ, Robinson C, Lam EW-F . 1993 Nucleic Acids Res. 21: 267–272
Weinberg R . 1995 Cell 81: 323–330
Ziebold U, Bartsch O, Marais R, Ferrari S, Klempnauer KH . 1997 Curr. Biol. 7: 253–260
Ziebold U, Klempnauer KH . 1997 Oncogene 15: 1011–1019
Acknowledgements
We thank Richard Eckner for kindly providing CBP monoclonal antibodies. This work was partially supported by a Cancer Research Campaign [CRC] project grant (SP2358/0101).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bessa, M., Saville, M. & Watson, R. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator. Oncogene 20, 3376–3386 (2001). https://doi.org/10.1038/sj.onc.1204439
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204439
Keywords
This article is cited by
-
Cathepsin L induced PC-12 cell apoptosis via activation of B-Myb and regulation of cell cycle proteins
Acta Pharmacologica Sinica (2019)
-
NF-Y is essential for expression of the proapoptotic bim gene in sympathetic neurons
Cell Death & Differentiation (2011)
-
A Lin-9 complex is recruited by B-Myb to activate transcription of G2/M genes in undifferentiated embryonal carcinoma cells
Oncogene (2009)
-
A B-Myb complex containing clathrin and filamin is required for mitotic spindle function
The EMBO Journal (2008)
-
The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1
Oncogene (2004)